<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10070035</article-id>
    <article-id pub-id-type="pmid">36744935</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btad073</article-id>
    <article-id pub-id-type="publisher-id">btad073</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Note</subject>
        <subj-group subj-group-type="category-toc-heading">
          <subject>Genetics and Population Analysis</subject>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI01060</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DeepPheWAS: an R package for phenotype generation and association analysis for phenome-wide association studies</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2459-1020</contrib-id>
        <name>
          <surname>Packer</surname>
          <given-names>Richard J</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
        <aff>Leicester National Institute of Health and Care Research Biomedical Research Centre, <institution>Glenfield Hospital</institution>, Leicester LE5 4PW, <country country="GB">UK</country></aff>
        <xref rid="btad073-cor1" ref-type="corresp"/>
        <!--richard.packer@leicester.ac.uk-->
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Williams</surname>
          <given-names>Alex T</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hennah</surname>
          <given-names>William</given-names>
        </name>
        <aff><institution>Orion Pharma</institution>, Espoo 02200, <country country="FI">Finland</country></aff>
        <aff>Neuroscience Center, HiLIFE, <institution>University of Helsinki</institution>, Helsinki 00100, <country country="FI">Finland</country></aff>
        <aff>Institute for Molecular Medicine FIMM, HiLIFE, <institution>University of Helsinki</institution>, Helsinki 00100, <country country="FI">Finland</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Eisenberg</surname>
          <given-names>Micaela T</given-names>
        </name>
        <aff>Department of Genetics and Genome Biology, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shrine</surname>
          <given-names>Nick</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fawcett</surname>
          <given-names>Katherine A</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pearson</surname>
          <given-names>Willow</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1860-6337</contrib-id>
        <name>
          <surname>Guyatt</surname>
          <given-names>Anna L</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Edris</surname>
          <given-names>Ahmed</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
        <aff>Department of Bioanalysis, Faculty of Pharmaceutical Sciences, <institution>Ghent University</institution>, Gent 9000, <country country="BE">Belgium</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hollox</surname>
          <given-names>Edward J</given-names>
        </name>
        <aff>Department of Genetics and Genome Biology, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Marttila</surname>
          <given-names>Mikko</given-names>
        </name>
        <aff><institution>Orion Pharma</institution>, Espoo 02200, <country country="FI">Finland</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rao</surname>
          <given-names>Balasubramanya S</given-names>
        </name>
        <aff><institution>Orion Pharma</institution>, Nottingham NG1 2GB, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bratty</surname>
          <given-names>John Raymond</given-names>
        </name>
        <aff><institution>Orion Pharma</institution>, Nottingham NG1 2GB, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wain</surname>
          <given-names>Louise V</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
        <aff>Leicester National Institute of Health and Care Research Biomedical Research Centre, <institution>Glenfield Hospital</institution>, Leicester LE5 4PW, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8817-8908</contrib-id>
        <name>
          <surname>Dudbridge</surname>
          <given-names>Frank</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tobin</surname>
          <given-names>Martin D</given-names>
        </name>
        <aff>Department of Population Health Sciences, <institution>University of Leicester</institution>, Leicester LE1 7RH, <country country="GB">UK</country></aff>
        <aff>Leicester National Institute of Health and Care Research Biomedical Research Centre, <institution>Glenfield Hospital</institution>, Leicester LE5 4PW, <country country="GB">UK</country></aff>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Schwartz</surname>
          <given-names>Russell</given-names>
        </name>
        <role>Associate Editor</role>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="btad073-cor1">To whom correspondence should be addressed. <email>richard.packer@leicester.ac.uk</email></corresp>
    </author-notes>
    <pub-date pub-type="collection">
      <month>4</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-02-06">
      <day>06</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>2</month>
      <year>2023</year>
    </pub-date>
    <volume>39</volume>
    <issue>4</issue>
    <elocation-id>btad073</elocation-id>
    <history>
      <date date-type="received">
        <day>30</day>
        <month>8</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>06</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="editorial-decision">
        <day>29</day>
        <month>1</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>03</day>
        <month>2</month>
        <year>2023</year>
      </date>
      <date date-type="corrected-typeset">
        <day>03</day>
        <month>4</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="btad073.pdf"/>
    <abstract>
      <title>Abstract</title>
      <sec id="s1">
        <title>Summary</title>
        <p>DeepPheWAS is an R package for phenome-wide association studies that creates clinically curated composite phenotypes and integrates quantitative phenotypes from primary care data, longitudinal trajectories of quantitative measures, disease progression and drug response phenotypes. Tools are provided for efficient analysis of association with any genetic input, under any genetic model, with optional sex-stratified analysis, and for developing novel phenotypes.</p>
      </sec>
      <sec id="s2">
        <title>Availability and implementation</title>
        <p>The DeepPheWAS R package is freely available under GNU general public licence v3.0 from at <ext-link xlink:href="https://github.com/Richard-Packer/DeepPheWAS" ext-link-type="uri">https://github.com/Richard-Packer/DeepPheWAS</ext-link>.</p>
      </sec>
      <sec id="s4">
        <title>Supplementary information</title>
        <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Bioinformatics</italic> online.</p>
      </sec>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>University of Leicester</institution>
            <institution-id institution-id-type="DOI">10.13039/501100000738</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>Phenome-wide association studies (PheWASs) can be used to better understand the pleiotropic effects of genetic variants (<xref rid="btad073-B17" ref-type="bibr">Tyler <italic toggle="yes">et al.</italic>, 2016</xref>) and to inform drug development through target identification, target validation and use of variants that mimic drug effects to assess likely drug efficacy, safety and drug repurposing opportunities (<xref rid="btad073-B5" ref-type="bibr">Diogo <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btad073-B11" ref-type="bibr">Gill <italic toggle="yes">et al.</italic>, 2019</xref>; <xref rid="btad073-B12" ref-type="bibr">Khosravi <italic toggle="yes">et al.</italic>, 2019</xref>). PheWASs comprise two stages—phenotype generation and statistical association tests. There have been two widely applicable methods for phenotype generation: PHESANT (<xref rid="btad073-B15" ref-type="bibr">Millard <italic toggle="yes">et al.</italic>, 2018</xref>) and PheWAS-R (<xref rid="btad073-B3" ref-type="bibr">Carroll <italic toggle="yes">et al.</italic>, 2014</xref>). PHESANT creates phenotypes by extracting study-specific questionnaire and measurement data alongside linked hospital records in UK Biobank. PheWAS-R combines related international classification of disease version 9 and 10 (ICD-9/ICD-10) codes into clinically relevant groups termed phecodes. Both tools provide regression analysis for per-variant PheWAS for generated phenotypes using generalized linear models in R and produce Manhattan plots. Online PheWAS resources such as Open Targets Genetics (<xref rid="btad073-B10" ref-type="bibr">Ghoussaini <italic toggle="yes">et al.</italic>, 2021</xref>) do not perform new statistical tests. Instead, they are repositories for existing results from phenotypes generated by one of the two above tools or by individual genome-wide association studies (GWAS).</p>
    <p>These tools are useful, but have several key gaps:</p>
    <list list-type="order">
      <list-item>
        <p>The phenotypes generated rely on a single data field or coding ontology and do not take advantage of all available data, such as primary care data;</p>
      </list-item>
      <list-item>
        <p>Existing approaches do not provide tools for developing new phenotypes;</p>
      </list-item>
      <list-item>
        <p>For running per-variant PheWAS, running each regression model in R is computationally inefficient and can result in inflated type I error for low-frequency variants with a case–control imbalance (<xref rid="btad073-B14" ref-type="bibr">Ma <italic toggle="yes">et al.</italic>, 2013</xref>);</p>
      </list-item>
      <list-item>
        <p>Online resources such as Open Targets Genetics have limited flexibility. For example, they accept only single nucleotide polymorphisms (SNPs) and retrieve results only for genetic models tested. The user cannot specify when to use new data fields or updates to existing data fields (e.g. updated health records), and the user cannot specify their preferred statistical approach and outputs, such as false discovery rate (FDR).</p>
      </list-item>
    </list>
    <p>The platform we have developed, DeepPheWAS, addresses both phenotype generation and efficient association testing while incorporating the following developments that are not yet available in any single current platform or online resource:</p>
    <list list-type="roman-lower">
      <list-item>
        <p>Clinically curated composite phenotypes for selected health conditions that integrate different data types (including primary and secondary care data) to study phenotypes not well captured by current classification trees;</p>
      </list-item>
      <list-item>
        <p>Integration of quantitative phenotypes from primary care data, such as pathology records and clinical measures;</p>
      </list-item>
      <list-item>
        <p>Integration of disease progression phenotypes, longitudinal trajectories of quantitative measures and drug response measures;</p>
      </list-item>
      <list-item>
        <p>Clinically curated phenotype selection for traits that are extremely highly correlated;</p>
      </list-item>
      <list-item>
        <p>Efficient association testing, and type-1 error control using PLINK 2 firth fall-back regression.</p>
      </list-item>
      <list-item>
        <p>Flexible tests of additive, dominant, recessive and genotypic models;</p>
      </list-item>
      <list-item>
        <p>Inclusion of complex variants, such as copy number variants with a wide range of copy numbers (multiallelic CNVs);</p>
      </list-item>
      <list-item>
        <p>Ability to test genetic risk scores;</p>
      </list-item>
      <list-item>
        <p>Creation of phenotypes in sex-specific strata to run a sex-stratified PheWAS;</p>
      </list-item>
      <list-item>
        <p>Providing tools for generating novel phenotypes using a simple phenotype mapping process.</p>
      </list-item>
    </list>
  </sec>
  <sec>
    <title>2 Application of DeepPheWAS to UK biobank</title>
    <sec>
      <title>2.1 Analysis of quantitative phenotypes</title>
      <p>Our package can be applied to quantitative phenotypes derived from numerous data sources, including primary care data. For example, we created a phenotype using recorded levels of blood sodium in primary care records that is not yet included in any PheWAS platform. We applied DeepPheWAS to rs7193778 (nearest genes <italic toggle="yes">NFAT5</italic> and <italic toggle="yes">TERF2</italic>), previously associated with urate levels (<xref rid="btad073-B13" ref-type="bibr">Köttgen <italic toggle="yes">et al.</italic>, 2013</xref>). Our PheWAS shows various associations which are currently not documented in GWAS Catalog, most strongly with blood sodium levels (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p>
    </sec>
    <sec>
      <title>2.2 Highly correlated traits</title>
      <p>We applied our DeepPheWAS approach to rs2912062 (nearest genes <italic toggle="yes">ANGPT2</italic> and <italic toggle="yes">AGPAT5</italic>), shown to be associated with carotid intima-media thickness (IMT) (<xref rid="btad073-B16" ref-type="bibr">Strawbridge <italic toggle="yes">et al.</italic>, 2020</xref>), a phenotype not currently available in any PheWAS platform. By selecting a single representative measure taken from many individual measurements, DeepPheWAS can collapse highly correlated quantitative traits into single measures (in this case carotid IMT maximum and carotid IMT mean), reducing redundancy and improving power. We recapitulated known GWAS findings (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>).</p>
    </sec>
    <sec>
      <title>2.3 Flexibility with choice of genetic model</title>
      <p>To demonstrate the flexibility of DeepPheWAS we assessed the <italic toggle="yes">SERPINA1</italic> Z allele [rs28929474(T)] under additive and recessive genetic models. Patterns of association differed between models, including opposite estimated effect directions for this variant on forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC), consistent with previous findings (<xref rid="btad073-B7" ref-type="bibr">Fawcett <italic toggle="yes">et al.</italic>, 2021a</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S3 and S4</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3 and S4</xref>).</p>
    </sec>
    <sec>
      <title>2.4 Association tests for complex structural variation</title>
      <p>Human genomic variation includes variants which have more categories than SNPs. For example, the diploid human copy number of <italic toggle="yes">CCL3L1</italic> ranges from 0 to 8 in UK Biobank participants (<xref rid="btad073-B6" ref-type="bibr">Fawcett <italic toggle="yes">et al.</italic>, 2022</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref>). In such situations, association testing may be based on the measured copy number or on user-specified collapsed categories, requiring a flexible platform. We used DeepPheWAS to test association with <italic toggle="yes">CCL3L1</italic> copy number (coded 0–8) under a linear additive model; no associations reached an FDR threshold of 1% (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S6</xref>, the top 5 associations are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>), this recapitulates findings from earlier studies (<xref rid="btad073-B1" ref-type="bibr">Adewoye <italic toggle="yes">et al.</italic>, 2018</xref>; <xref rid="btad073-B2" ref-type="bibr">Carpenter <italic toggle="yes">et al.</italic>, 2011</xref>; <xref rid="btad073-B9" ref-type="bibr">Field <italic toggle="yes">et al.</italic>, 2009</xref>; <xref rid="btad073-B18" ref-type="bibr">Urban <italic toggle="yes">et al.</italic>, 2009</xref>).</p>
    </sec>
    <sec>
      <title>2.5 Genetic risk scores, composite and disease-progression phenotypes</title>
      <p>Genetic risk scores (GRS) aggregate multiple SNPs, providing improved power for studying phenotypic associations, but cannot be specified in online PheWAS platforms. We performed a PheWAS using a 279-variant GRS for FEV<sub>1</sub>/FVC (<xref rid="btad073-B6343233" ref-type="bibr">Shrine, 2019</xref>), which showed association (FDR &lt; 1%) with 47 traits including increased risk of clinical COPD and clinical asthma with a higher score of FEV<sub>1</sub>/FVC reducing alleles (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S7</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref>). Furthermore, the composite phenotypes generated by the DeepPheWAS platform (e.g. P2020 Asthma and P2054 COPD) were consistently more strongly associated with the GRS for FEV<sub>1</sub>/FVC than the relevant Phecodes alone. We also show significant association with the novel disease-progression phenotypes: exacerbation of COPD and age-of-onset of COPD both of which are unavailable in existing PheWAS resources and have published GWAS results.</p>
    </sec>
    <sec>
      <title>2.6 Sex-stratified PheWAS</title>
      <p>We applied DeepPheWAS to rs12777332 (nearest genes <italic toggle="yes">CASP7</italic> and <italic toggle="yes">NRAP</italic>) and rs7697189 (nearest gene <italic toggle="yes">HHIP</italic>). We replicate association for risk of cataract in women only (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S8</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S7</xref>) for rs12777332 (<xref rid="btad073-B4" ref-type="bibr">Choquet <italic toggle="yes">et al.</italic>, 2021</xref>), and for increased effect on FEV<sub>1</sub> in men compared to women (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figs S9 and S10</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S8</xref>) for rs7697189 (<xref rid="btad073-B8" ref-type="bibr">Fawcett <italic toggle="yes">et al.</italic>, 2021b</xref>).</p>
    </sec>
  </sec>
  <sec>
    <title>3 Implementation</title>
    <p>DeepPheWAS is an R package that can be run on high-performance computing clusters and requires R 4.1.0 and PLINK 2.0. DeepPheWAS is optimized for UK Biobank data and is expected to be interoperable with the UK Biobank Research Analysis Platform, further details on required data can be seen in the supplement and on <ext-link xlink:href="https://richard-packer.github.io/DeepPheWAS_site/" ext-link-type="uri">https://richard-packer.github.io/DeepPheWAS_site/</ext-link>.</p>
  </sec>
  <sec>
    <title>4 Availability</title>
    <p>The DeepPheWAS R package is freely available under GNU general public licence v3.0 from at <ext-link xlink:href="https://github.com/Richard-Packer/DeepPheWAS" ext-link-type="uri">https://github.com/Richard-Packer/DeepPheWAS</ext-link>.</p>
  </sec>
  <sec>
    <title>5 Conclusion</title>
    <p>Here, we present DeepPheWAS, an R package that facilitates phenome-wide association studies while addressing several limitations of existing approaches. This includes the ability to analyse a broader range of phenotypes derived from large-scale electronic healthcare records, more informative composite phenotypes, greater flexibility in the type of genetic variation that can be studied and assessing associations with genetic risk scores.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>btad073_Supplementary_Data</label>
      <media xlink:href="btad073_supplementary_data.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ack1">
    <title>Acknowledgements</title>
    <p>This research has been conducted using UK Biobank Resource under Application Number 43027. This research used the SPECTRE High Performance Computing Facility at the University of Leicester.</p>
  </ack>
  <sec>
    <title>Funding</title>
    <p>This work was supported by Orion Pharma who funded a research collaboration with the University of Leicester, which supported the development of DeepPheWAS; Wellcome Trust Institutional Strategic Support Fund [204801/Z/16/Z], BHF Accelerator Award [AA/18/3/34220] to A.L.G.; GSK/Asthma + Lung UK Chair in Respiratory Research (C17-1) to L.V.W.; Wellcome Trust Investigator Award [WT202849/Z/16/Z to M.D.T.]; M.D.T. holds an National Institute for Health and Care Research Senior Investigator Award. The respiratory research was partially supported by BREATHE—The Health Data Research Hub for Respiratory Health [MC_PC_19004]. The research was partially supported by the National Institute for Health and Care Research Leicester Biomedical Research Centre; views expressed are those of the author(s) and not necessarily those of the NHS, the National Institute for Health and Care Research or the Department of Health. This research was funded in part by the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.</p>
    <p><italic toggle="yes">Conflict of interest</italic>: M.D.T., R.P., A.T.W., F.D. and L.V.W. received funding from Orion Pharma within the scope of the submitted work and from GSK for collaborative research projects outside of the submitted work. W.H., B.S.R., M.M. and R.B. are salaried employees of Orion Pharma within the scope of the submitted work. L.V.W. has performed consultancy for Galapagos and had travel paid for by Genetech outside the scope of this work.</p>
  </sec>
  <sec sec-type="data-availability">
    <title>Data availability</title>
    <p>The data underlying this article are available from the UK Biobank to all approved researchers <ext-link xlink:href="https://www.ukbiobank.ac.uk/" ext-link-type="uri">https://www.ukbiobank.ac.uk/</ext-link>. Data were accessed under approved application 43027.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="btad073-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adewoye</surname><given-names>A.B.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Human CCL3L1 copy number variation, gene expression, and the role of the CCL3L1-CCR5 axis in lung function</article-title>. <source>Wellcome Open Res</source>., <volume>3</volume>, <fpage>13</fpage>.<pub-id pub-id-type="pmid">29682616</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carpenter</surname><given-names>D.</given-names></string-name></person-group><etal>et al</etal> (<year>2011</year>) <article-title>Accuracy and differential bias in copy number measurement of CCL3L1 in association studies with three auto-immune disorders</article-title>. <source>BMC Genomics</source>, <volume>12</volume>, <fpage>418</fpage>.<pub-id pub-id-type="pmid">21851606</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carroll</surname><given-names>R.J.</given-names></string-name></person-group><etal>et al</etal> (<year>2014</year>) <article-title>R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment</article-title>. <source>Bioinformatics</source>, <volume>30</volume>, <fpage>2375</fpage>–<lpage>2376</lpage>.<pub-id pub-id-type="pmid">24733291</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Choquet</surname><given-names>H.</given-names></string-name></person-group><etal>et al</etal>; <collab>23andMe Research Team</collab> (<year>2021</year>) <article-title>A large multiethnic GWAS meta-analysis of cataract identifies new risk loci and sex-specific effects</article-title>. <source>Nat. Commun</source>., <volume>12</volume>, <fpage>3595</fpage>.<pub-id pub-id-type="pmid">34127677</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Diogo</surname><given-names>D.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Phenome-wide association studies across large population cohorts support drug target validation</article-title>. <source>Nat. Commun</source>., <volume>9</volume>, <fpage>4285</fpage>.<pub-id pub-id-type="pmid">30327483</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fawcett</surname><given-names>K.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2022</year>) <article-title>Exome-wide analysis of copy number variation shows association of the human leukocyte antigen region with asthma in UK Biobank</article-title>. <source>BMC Med. Genomics</source>, <volume>15</volume>, <fpage>119</fpage>.<pub-id pub-id-type="pmid">35597955</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fawcett</surname><given-names>K.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2021a</year>) <article-title>Pleiotropic associations of heterozygosity for the <italic toggle="yes">SERPINA1</italic> Z allele in the UK biobank</article-title>. <source>ERJ Open Res</source>., <volume>7</volume>, <fpage>00049</fpage>-<lpage>2021</lpage>.<pub-id pub-id-type="pmid">33981765</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fawcett</surname><given-names>K.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2021b</year>) <article-title>Variants associated with HHIP expression have sex-differential effects on lung function</article-title>. <source>Wellcome Open Res</source>., <volume>5</volume>, <fpage>111</fpage>.<pub-id pub-id-type="pmid">33728380</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Field</surname><given-names>S.F.</given-names></string-name></person-group><etal>et al</etal> (<year>2009</year>) <article-title>Experimental aspects of copy number variant assays at CCL3L1</article-title>. <source>Nat. Med</source>., <volume>15</volume>, <fpage>1115</fpage>–<lpage>1117</lpage>.<pub-id pub-id-type="pmid">19812562</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ghoussaini</surname><given-names>M.</given-names></string-name></person-group><etal>et al</etal> (<year>2021</year>) <article-title>Open targets genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics</article-title>. <source>Nucleic Acids Res</source>., <volume>49</volume>, <fpage>D1311</fpage>–<lpage>D1320</lpage>.<pub-id pub-id-type="pmid">33045747</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gill</surname><given-names>D.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Use of genetic variants related to antihypertensive drugs to inform on efficacy and side effects</article-title>. <source>Circulation</source>, <volume>140</volume>, <fpage>270</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">31234639</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khosravi</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data</article-title>. <source>Mol. Med</source>., <volume>25</volume>, <fpage>30</fpage>.<pub-id pub-id-type="pmid">31221082</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Köttgen</surname><given-names>A.</given-names></string-name></person-group><etal>et al</etal>; <collab>MAGIC Consortium</collab> (<year>2013</year>) <article-title>Genome-wide association analyses identify 18 new loci associated with serum urate concentrations</article-title>. <source>Nat. Genet</source>., <volume>45</volume>, <fpage>145</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">23263486</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>C.</given-names></string-name></person-group><etal>et al</etal>; <collab>GoT2D Investigators</collab>. (<year>2013</year>) <article-title>Recommended joint and meta-analysis strategies for case-control association testing of single low-count variants: joint and meta-analysis of low-count variants</article-title>. <source>Genet. Epidemiol</source>., <volume>37</volume>, <fpage>539</fpage>–<lpage>550</lpage>.<pub-id pub-id-type="pmid">23788246</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Millard</surname><given-names>L.A.</given-names></string-name></person-group><etal>et al</etal> (<year>2018</year>) <article-title>Software application profile: PHESANT: a tool for performing automated phenome scans in UK Biobank</article-title>. <source>Int. J. Epidemiol</source>., <volume>47</volume>, <fpage>29</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">29040602</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B6343233">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shrine</surname>,<given-names>N.</given-names></string-name></person-group><etal>et al</etal> (<year>2019</year>) <article-title>New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries</article-title>. <source>Nat. Genet.</source>, <volume>51</volume>, <fpage>481</fpage>–<lpage>493</lpage>.<pub-id pub-id-type="pmid">30804560</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strawbridge</surname><given-names>R.J.</given-names></string-name></person-group><etal>et al</etal> (<year>2020</year>) <article-title>Carotid intima-media thickness: novel loci, sex-specific effects, and genetic correlations with obesity and glucometabolic traits in UK Biobank</article-title>. <source>Arterioscler. Thromb. Vasc. Biol</source>., <volume>40</volume>, <fpage>446</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">31801372</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tyler</surname><given-names>A.L.</given-names></string-name></person-group><etal>et al</etal> (<year>2016</year>) <article-title>The detection and characterization of pleiotropy: discovery, progress, and promise</article-title>. <source>Brief. Bioinform</source>., <volume>17</volume>, <fpage>13</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">26223525</pub-id></mixed-citation>
    </ref>
    <ref id="btad073-B18">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Urban</surname><given-names>T.J.</given-names></string-name></person-group><etal>et al</etal> (<year>2009</year>) <article-title>CCL3L1 and HIV/AIDS susceptibility</article-title>. <source>Nat. Med</source>., <volume>15</volume>, <fpage>1110</fpage>–<lpage>1112</lpage>.<pub-id pub-id-type="pmid">19812560</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
